Denise Myshko

The monthly price of the 2.5 mg Zepbound single-dose vial is $399 and the 5 mg dose is $549, which Lilly officials said is in line with the savings program for without insurance.

Beginning in 2025, Express Scripts will favor biosimilars of Humira, including its own private-label version.

The updated vaccines include the KP.2 strain of the Omicron variant, which is believed to be contributing to the increases in COVID-19 infections this summer.

Avalere’s Kylie Stengel talks about the regional shifts in formularies and utilization management in Medicare Part D prescription drug plans.

Researchers in a new study found that the overall risk of RSV-related hospitalization for adults with inflammatory bowel disease was greatest for those who were 18 to 49 years of age and those who were 65 years of age or older.

The Medicare program is expected to see some aggregate savings from the negotiated drug prices. Beneficiaries, because of out-of-pocket caps next year, may not see the benefit, that is until the next round or two of negotiations if CMS choses drugs that are not heavily rebated.

The negotiated prices range from 38% to 79% discounts off of list prices, according to the Department of Health and Human Services.

New research looks at the impact of state-level caps on out-of-pocket costs for insulin. Before the caps, most commercial enrollees were already paying costs below the cap amounts.

The KFF analysis reported on the number of prior authorizations by plans, but found the data do not contain enough information to assess prior authorization by type of service, type of plan or reasons for denials.

Prademagene zamikeracel is a cell therapy in development to treat patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder.

Merck and Johnson & Johnson have both acquired bispecific antibodies with applications in autoimmune and inflammatory conditions.

No information, however, is available about which insurance plans are providing coverage of Anktiva or what the utilization management requirements are.

New analysis shows that differences in the methods used to set drug payment amounts under Part B versus under Part D result in different payment amounts for the same drugs.

In a recent survey, payers said their priorities include addressing the impacts of Medicare’s Drug Price Negotiation Program and the Part D redesign.

Total revenue for the company increased for the second quarter of 2024, but CVS Health is facing increased medical cost trend in its Medicare/Medicaid health plans and lowered revenue in its pharmacy benefit business. As a result, CVS Health has lowed its outlook for the year and parted ways with its Aetna president.

After less than a year, Aetna president Brian Kane is out at CVS Health, it was announced today at an investor call. The change was made to address the continued pressure in the company’s healthcare benefits business.

SelfJect is priced at parity with the Acthar Gel multi-dose vial and syringe.

Driving this growth will be the approvals of novel biologics, such as gene therapy, RNA-based therapeutics, and antibody-drug conjugates.

Medicaid children with type 1 diabetes are three times more likely to receive metformin than commercial enrollees even though metformin is only indicated for use in patients with type 2 diabetes.

Cigna officials cite significant growth in Evernorth Health Services and Express Scripts for the increase in revenue.

As many as 40% of people with type 1 diabetes are unaware that they have the disease.

Suzetrigine, a new type of pain medication, has a Prescription Drug User Fee Act target action date of Jan. 30, 2025, for patients with acute pain.

CVS Caremark is requiring step therapy through a generic prescription proton pump inhibitor before providing coverage.

Higher costs per claim, coupled with an increased number of patients using specialty drugs, has contributed to higher spend.

Keri Althoff, Ph.D., discusses how a model developed at Johns Hopkins can assess the comorbidities that patients with HIV may face by 2030.

Improving equity for people with HIV requires health leaders to recognize that patients have different risk factors, Keri Althoff, Ph.D., of Johns Hopkins says.

A substudy of the FLAIR phase 3 trial found that participants favored intramuscular injection of Cabenuva over the subcutaneous version due to pain and the development of nodules and reddening of the skin.

There is still much to be done to build on the progress already made in HIV and AIDS, panelists said during a session at the International AIDS Conference.

Results from the DYAD trial reinforce a previous study that found Dovato is not inferior for patients with undetectable viral load who switched from Biktarvy

The FDA has required all approved CAR T therapies to have a boxed warning about the risk of secondary malignancies after treatment.